cytokine-panels-and-their-role-in-multiplex-cytokine Videos
7 videos found
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies and Cytokine ...
Nov. 30, 2022
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies and Cytokine ...
Nov. 30, 2022
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies and Cytokine ...
Nov. 30, 2022
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies and Cytokine ...
Nov. 30, 2022
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies and Cytokine ...
Nov. 30, 2022
Cytosorb®? is approved in the European Union with distribution in 65 countries around the world. CytoSorb is indicated for use in conditions where elevated levels of cytokine and/or bilirubin and/or myoglobin exist. CytoSorb is indicated for use intraoperatively during cardio-pulmonary bypass surgery for removal of the P2Y12 inhibitor Ticagrelor and/or the Factor Xa inhibitor Rivaroxaban. The ...
Apr. 19, 2022
Biotron Limited (ASX:BIT) held a webinar today to update investors on its latest news on its lead clinical stage antiviral drug BIT225. BIT225 has shown significant and clinically relevant activity in an animal model of COVID-19. The drug prevented the development of severe disease, reduced pro-inflammatory cytokines associated with "cytokine storms" that are linked to severe disease and ...
Jun. 2, 2022